樊嘉精准医学时代肝细胞癌的系统治疗专家视角(7)
[44]LEE JJX, CHAN JJ, CHOO SP. Clinical development of c-MET inhibition in hepatocellular carcinoma[J]. Diseases, 2015, 3(4): 306-324.
[45]RIMASSA L, ABBADESSA G, PERSONENI N, et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib[J]. Oncotarget, 2016, 7(45): -.
[46]JIANG Y, SUN A, ZHAO Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]. Nature, 2019, 567(7747): 257-261.
引证本文
樊嘉, 等. 精准医学时代肝细胞癌的系统治疗[J]. 临床肝胆病杂志, 2020, 36(10): 2173-2178.
本文编辑:朱晶
公众号编辑:邢翔宇
文章来源:《精准医学杂志》 网址: http://www.jzyxzz.cn/zonghexinwen/2020/1110/343.html